Title

Molecular mechanisms and mode of tamoxifen resistance in breast cancer

Authors

Shazia Ali1, Mahmood Rasool2, Hani Chaoudhry3,Peter N Pushparaj2, Parkash Jha4, Abdul Hafiz5,
Maryam Mahfooz4, Ghufrana Abdus Sami6, Mohammad Azhar Kamal7, Sania Bashir6, Ashraf
Ali7and Mohammad Sarwar Jamal7*,

Affiliation

1School of life science, Jawaharlal Nehru University, New Delhi, India; 2Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia; 3Department of Biochemistry, Faculty of Science, Center of Innovation in Personalized Medicine, King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia; 4Department of Computer
Science, Jamia Millia Islamia, New Delhi, India; 5Ummul Qura University, Makkah, Saudi Arabia; 6Department of Biotechnology, Jamia Millia Islamia, New Delhi, India; 7King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia;

Email

Mohammad Sarwar Jamal - Email: sarwar4u@gmail.com; *Corresponding author

Article Type

Hypothesis

Date

Received March 20, 2016; Revised May 2, 2016; Accepted May 5, 2016; Published June 15, 2016

Breast cancer is one of the most common cancers in women around the globe Tamoxifen is used for the last 40 years as an endocrine therapy for breast cancer. This resulted in the reduction of mortality rate by 30% and it still remains one of the most effective therapies against breast cancer. However, resistance against tamoxifen is still one of the major hurdles in the effective management of breast cancer. Intense research has been conducted in the past decade to further explore its resistance mechanism, but still a lot of research will be needed to effectively alleviate this problem. Several biochemical factors and molecular pathways, such as the modulation of ER signaling, upregulation of growth factors had been observed as key factors for tamoxifen resistance (TR). After, initial therapy of five to ten years, breast cancer patients develops resistance towards this drug. The resistance leads to the development of other cancers like uterine cancer. Here, we briefly explore all the molecular events related to tamoxifen resistance and focus on its mechanism of action as well as other pharmacological approaches to better its beneficial effects in the treatment of breast carcinoma.

Keywords

Breast carcinoma; Estrogen receptor; Tamoxifen resistance; Endocrine therapy

Citation

Ali et al. Bioinformation 12(3): 135-139 (2016)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.